Petition to the FDA to Ban Olmesartan-Containing Hypertension Medications

November 15, 2017

View as PDF.

View press release.

November 15, 2017, FDA acknowledgment letter.

May 11, 2018, FDA interim response letter.

Public Citizen petitioned the Food and Drug Administration (FDA) to ban the sale of olmesartan medoxomil – an angiotensin II receptor blocker (ARB) found in the widely prescribed hypertension medications marketed under the brand names Azor, Benicar, Benicar HCT and Tribenzor, as well as in other generic versions – because it can cause a severe gastrointestinal disorder that leads to severe and chronic diarrhea, vomiting, abdominal pain and weight loss.